Results 101 to 110 of about 52,475 (270)

Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study. [PDF]

, 2018
Aims: In Europe, the approved rivaroxaban dose for stroke prevention in patients with atrial fibrillation is 20 mg once daily (od), with 15 mg od recommended in patients with creatinine clearance [CrCl] 15-49 mL/min.
Bayer, Camm, Camm, Camm, Chugh, Connolly, Giugliano, Granger, Kirchhof, Patel, Ruff, Schulman, Steinberg, Steinberg   +13 more
core   +2 more sources

Clinical experience of the use of the combination of clopidogrel and rivaroxaban in dogs with aortic thrombosis: case series of 8 dogs [PDF]

, 2023
Vasiliki Lantzaki
openalex   +1 more source

Relation of the stress hyperglycaemia ratio to residual risk in anticoagulated patients with atrial fibrillation: A report from the prospective Murcia AF Project III cohort

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Introduction Atrial fibrillation (AF) carries residual thromboembolic and cardiovascular risk despite oral anticoagulation (OAC). The stress hyperglycaemia ratio (SHR), derived from admission glucose and glycated haemoglobin (HbA1c), integrates information on both acute glycaemic fluctuations and chronic glycaemic burden.
Eva Soler‐Espejo, Yang Chen, José Miguel Rivera‐Caravaca, José Antonio Sánchez‐Salas, María Asunción Esteve‐Pastor, Francisco Marín, Vanessa Roldán, Gregory Y. H. Lip   +7 more
wiley   +1 more source

Major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation:Contemporary findings in real-life Danish patients [PDF]

, 2017
Background The nonvitamin K antagonist oral anticoagulants have recently become available as an alternative to warfarin as stroke prophylaxis in atrial fibrillation, but data on real‐life patient experience, including bleeding ...
Evans, David, Fosbøl, Emil Loldrup, Gislason, Gunnar Hilmar, Hansen, Morten Lock, Harboe, Louise, Lamberts, Morten, Lefevre, Cinira, Olesen, Jonas Bjerring, Staerk, Laila   +8 more
core   +3 more sources

Effectiveness of direct oral anticoagulants for all‐cause mortality and cardiovascular events in overweight and obese patients with atrial fibrillation: Insight from the nationwide START registry

European Journal of Clinical Investigation, EarlyView.
This study shows that overweight and obese patients with atrial fibrillation experience improved outcomes when treated with DOACs compared with VKAs. Specifically, DOAC use was associated with lower risks of all‐cause mortality and cardiovascular events.
Danilo Menichelli, Gianluca Gazzaniga, Emilia Antonucci, Gualtiero Palareti, Daniela Poli, Pasquale Pignatelli, Daniele Pastori, the START2 Register Investigators, Benilde Cosmi, Daniela Poli, Elena Lotti, Martina Berteotti, Walter Ageno, Giovanna Colombo, Salvatore Bradamante, Eugenio Bucherini, Monica Vastola, Paola Casasco, Antonio Chistolini, Alessandra Serrao, Luciano Crippa Ambulatorio Emostasi, Raimondo De Cristofaro, Erica De Candia, Valeria De Micheli, Marcello Di Nisio, Anna Falanga, Teresa Lerede, Elvira Grandone, Donatella Colaizzo, Antonio Insana, Nicola Lucio Liberato, Domenico Lione, Rosa Maria Lombardi, Giacomo Lucarelli, Giuseppe Malcangi, Catello Mangione, Giuliana Martini Centro Emostasi, Marco Marzolo, Giovanni Nante, Vincenzo Oriana, Paolo Pedico, Simona Pedrini, Vittorio Pengo, Antonietta Piana, Francesco Cibecchini, Simona Pezzella, Pasquale Pignatelli, Daniele Pastori, Vincenza Rossi, Lucia Ruocco, Paolo Chiarugi, Serena Rupoli, Domizio Serra, Carmine Spataro, Margherita Reduzzi, Sophie Testa, Oriana Paoletti, Vincenzo Toschi, Claudio Vasselli   +58 more
wiley   +1 more source

Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation

Therapeutics and Clinical Risk Management, 2014
Alexander GG Turpie Department of Medicine, McMaster University, Hamilton, ONT, Canada Abstract: Atrial fibrillation (AF) is the most common cardiac arrhythmia in the developed world and is associated with a fivefold increase in the risk of stroke ...
Turpie AGG
doaj  

Physiologically‐Based Pharmacokinetic Modeling for the Prediction of a Drug–Drug Interaction of Combined Effects on P‐glycoprotein and Cytochrome P450 3A

CPT: Pharmacometrics & Systems Pharmacology, 2020
Direct oral anticoagulants, such as apixaban and rivaroxaban, are important for the treatment and prophylaxis of venous thromboembolism and to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Yukio Otsuka, Mary P. Choules, Peter L. Bonate, Kanji Komatsu   +3 more
doaj   +1 more source

Bilateral abducens nerve palsy due to septic thrombophlebitis. [PDF]

, 2019
PurposeTo report a case of septic thrombophlebitis producing bilateral abducens nerve palsy.ObservationA 65 year-old woman with recent sinus surgery experienced the onset of horizontal diplopia during treatment for bacteremia. Computer tomography of head
Robbins, Shira L, Savino, Peter J, Vu, Vincent N   +2 more
core  

Global Prospective Safety Analysis of Rivaroxaban. [PDF]

, 2018
BACKGROUND: The efficacy of direct oral anticoagulants (DOACs) for stroke prevention in patients with atrial fibrillation (AF) has been established in clinical trials.
A. John Camm, Alexander G.G. Turpie, Camm, Camm, Camm, Camm, Chugh, Coleman, Coleman, Connolly, Fernando Lanas, Ghazi Radaideh, Giugliano, Granger, Healey, Hecker, January, Jose, Kirchhof, Kirchhof, Kirchhof, Ligthelm, Lip, Marc Lambelet, Miriam Bach, Nieuwlaat, Patel, Paulus Kirchhof, Peacock, Pierre Amarenco, Ruff, Steinberg, Sun, Susanne Hess, Sylvia Haas, Tsai, Wong, Young-Hoon Kim, Zoni-Berisso   +38 more
core   +2 more sources

Measuring Direct Oral Anticoagulant (DOAC) Levels: Applications, Limitations, and Future Directions

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction There are important challenges with the measurement and interpretation of direct oral anticoagulant (DOAC) anticoagulant effect including a lack of therapeutic ranges, inaccuracy of routinely available coagulation assays, lack of established thresholds for clinically significant effect, and uncertainty about how to apply the ...
Siraj Mithoowani, Chee Wee Tan, Deborah M. Siegal   +2 more
wiley   +1 more source